Recombinant Human APRIL/TNFSF13 (HEK293-expressed), CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

APRIL (a proliferation-inducing ligand), also known as TNFSF13, TALL2, TRDL1, and CD256, is a member of the TNF ligand superfamily (1). It is synthesized as a 32 kDa proprotein which is cleaved by furin in the Golgi to release the active 17 kDa soluble molecule (2-4). Secreted human APRIL, which consists almost entirely of a single TNF homology domain, shares 85% amino acid sequence identity with mouse and rat APRIL (2, 3). Both APRIL and its close relative BAFF bind and signal through the TNF superfamily receptors TACI and BCMA, while BAFF additionally functions through BAFF R (2, 5, 6). APRIL binds to heparan sulfate proteoglycans (HSPGs) independently of its binding to TACI and BCMA (6, 7). The interaction with HSPGs induces APRIL oligomerization, and this augments TACI-, or BMCA-mediated effects (7, 8). HSPGs are also critical for the tumor growth-promoting effects attributed to APRIL (6). APRIL can form bioactive heterotrimers with BAFF, and these circulate in the serum of patients with rheumatic immune disorders (10). TWE-PRIL is a bioactive hybrid protein produced by gene splicing. It consists of the intracellular domain, transmembrane segment, and stalk region of TWEAK fused to the TNF homology domain of APRIL (11). TWE-PRIL is expressed in monocytes and activated T cells and, in contrast to APRIL, is presented on the cell surface (11). APRIL enhances the proliferation and survival of plasma cells and also promotes T cell-dependent humoral responses (2, 12, 13). In the context of autoimmune disorders, however, APRIL can inhibit pathologic humoral responses as well as disease progression (14). Its expression by CD4⁺ T cells inhibits the production of Th2 cytokines and allergic inflammation (15). APRIL levels are elevated in the serum during coronary artery disease (16), and it is also elevated in many cancers primarily due to expression by tumor-infiltrating neutrophils (4, 7, 17).

We have publications tested in 1 confirmed species: Human.

We have publications tested in 2 applications: Bioassay, Surface Plasmon Resonance (SPR.

Showing Publications 1 - 10 of 10.

Publications using 5860-AP/CF	Applications	Species
CC Chan, ITW Harley, PT Pfluger, A Trompette, TE Stankiewic, JL Allen, ME Moreno-Fer, MSMA Damen, JR Oates, PC Alarcon, JR Doll, MJ Flick, LM Flick, J Sanchez-Gu, R Mukherjee, R Karns, M Helmrath, TH Inge, SP Weisberg, SJ Pamp, DA Relman, RJ Seeley, MH Tschöp, CL Karp, S Divanovic A BAFF/APRIL axis regulates obesogenic diet-driven weight gain Nature Communications, 2021-05-18;12(1):2911. 2021-05-18 [PMID: 34006859] (Bioassay, Human)	Bioassay	Human
M Mulazzani, M Huber, S Borchard, S Langer, B Angele, E Schuh, E Meinl, M Dreyling, T Birnbaum, A Straube, U Koedel, L von Baumga APRIL and BAFF: novel biomarkers for central nervous system lymphoma J Hematol Oncol, 2019-10-15;12(1):102. 2019-10-15 [PMID: 31615554] (Bioassay, Human)	Bioassay	Human
R Wilson, M Makuch, AK Kienzler, J Varley, J Taylor, M Woodhall, J Palace, MI Leite, P Waters, SR Irani Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica Brain, 2018-04-01;141(4):1063-1074. 2018-04-01 [PMID: 29447335] (Bioassay, Human)	Bioassay	Human
AW Clarke, L Poulton, D Shim, D Mabon, D Butt, M Pollard, V Pande, J Husten, J Lyons, C Tian, AG Doyle An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease MAbs, 2018-03-05;0(0):1-43. 2018-03-05 [PMID: 29436901] (Surface Plasmon Resonance (SPR, Human)	Surface Plasmon Resonance (SPR	Human
D Brach, D Johnston-B, A Drew, T Lingaraj, V Motwani, NM Warholic, I Feldman, C Plescia, JJ Smith, RA Copeland, H Keilhack, E Chan-Peneb, SK Knutson, SA Ribich, A Raimondi, MJ Thomenius EZH2 inhibition by tazemetostat results in altered dependency on B-cell activation signaling�in DLBCL Mol. Cancer Ther., 2017-08-23;0(0):. 2017-08-23 [PMID: 28835384] (Bioassay, Human)	Bioassay	Human
Saulep-Easton D, Vincent F, Quah P, Wei A, Ting S, Croce C, Tam C, Mackay F The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells. Leukemia, 2015-07-03;30(1):163-72. 2015-07-03 [PMID: 26139429] (Bioassay, Human)	Bioassay	Human
Mamara , Antigoni, Germenis , Anastasi, Kompoti , Maria, Palassopoulou , Maria, Mandala , Eudokia, Banti , Anastasi, Giannakoulas , Nikolaos, Speletas , Matthaio TACI expression and signaling in chronic lymphocytic leukemia. J Immunol Res, 2015-04-09;2015(0):478753. 2015-04-09 [PMID: 25950010] (Bioassay, Human)	Bioassay	Human
Deknuydt F, Nordstrom T, Riesbeck K Diversion of the host humoral response: a novel virulence mechanism of Haemophilus influenzae mediated via outer membrane vesicles. J Leukoc Biol, 2014-02-18;95(6):983-91. 2014-02-18 [PMID: 24550522] (Bioassay, Human)	Bioassay	Human
Osorio C, Chacon P, White M, Kisiswa L, Wyatt S, Rodriguez-Tebar A, Davies A Selective regulation of axonal growth from developing hippocampal neurons by tumor necrosis factor superfamily member APRIL. Mol Cell Neurosci, 2014-01-18;59(0):24-36. 2014-01-18 [PMID: 24444792] (Bioassay, Human)	Bioassay	Human
Tai Y, Landesman Y, Acharya C, Calle Y, Zhong M, Cea M, Tannenbaum D, Cagnetta A, Reagan M, Munshi A, Senapedis W, Saint-Martin J, Kashyap T, Shacham S, Kauffman M, Gu Y, Wu L, Ghobrial I, Zhan F, Kung A, Schey S, Richardson P, Munshi N, Anderson K CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia, 2013-04-16;28(1):155-65. 2013-04-16 [PMID: 23588715] (Bioassay, Human)	Bioassay	Human

Array 5860-AP/CF

• APRIL/TNFSF13 Antibodies
• APRIL/TNFSF13 ELISA Kit
• APRIL/TNFSF13 Lysates
• APRIL/TNFSF13 Proteins
• APRIL/TNFSF13 ELISA
• APRIL/TNFSF13 Proteins and Enzymes